Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huanghe decoction is a Traditional Chinese Medicine (TCM) formula developed by The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine for the treatment of allergic rhinitis, specifically targeting the lung-spleen qi deficiency syndrome. The formula is composed of several botanical ingredients, including *Astragalus membranaceus* (Huangqi) and *Nelumbo nucifera* (He Ye), which are thought to work synergistically to modulate the immune system. Its mechanism of action involves balancing the Th1/Th2 immune response by suppressing the production of Th2-associated cytokines like interleukin-4 (IL-4) and promoting Th1-associated cytokines such as interferon-gamma (IFN-γ). This shift leads to a reduction in serum immunoglobulin E (IgE) levels and the stabilization of mast cells, thereby alleviating clinical symptoms such as nasal itching, sneezing, and rhinorrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huanghe decoction.